Kommanditgesellschaft

DGAP-News: dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.

Retrieved on: 
Thursday, January 13, 2022 - 10:08pm

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
  • dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
    WALLDORF / BERLIN , Germany - 13 January 2022 - Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt fr Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (Nasdaq: CVAC).
  • In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares.
  • Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

Global Laboratory Glassware & Plasticware Market (2021 to 2027) - by Products, End-users and Geography - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 9, 2021 - 5:40pm

The "Global Laboratory Glassware & Plasticware Market (2021-2027) by Products, End Users and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Laboratory Glassware & Plasticware Market (2021-2027) by Products, End Users and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Laboratory Glassware & Plasticware Market is estimated to be USD 6.2 Bn in 2021 and is expected to reach USD 7.71 Bn by 2027, growing at a CAGR of 3.7%.
  • are expected to be the major drivers for the market growth of global laboratory glassware & plasticware market.
  • The Global Laboratory Glassware & Plasticware Market is segmented further based on Products, End Users and Geography.

DGAP-News: Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 (MAR); Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052

Retrieved on: 
Monday, November 29, 2021 - 7:05pm

Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.

Key Points: 
  • Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.
  • (EU) No 596/2014 (MAR); Article 6 (2) of the Com.
  • Delegated Reg.
  • (EU) 2016/1052 (news with additional features)
    The issuer is solely responsible for the content of this announcement.

DGAP-News: Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 (MAR); Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052

Retrieved on: 
Monday, November 22, 2021 - 9:06pm

Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.

Key Points: 
  • Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.
  • (EU) No 596/2014 (MAR); Article 6 (2) of the Com.
  • Delegated Reg.
  • (EU) 2016/1052 (news with additional features)
    The issuer is solely responsible for the content of this announcement.

DGAP-News: Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 (MAR); Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052

Retrieved on: 
Monday, November 15, 2021 - 7:05pm

Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.

Key Points: 
  • Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.
  • (EU) No 596/2014 (MAR); Article 6 (2) of the Com.
  • Delegated Reg.
  • (EU) 2016/1052 (news with additional features)
    The issuer is solely responsible for the content of this announcement.

DGAP-News: dievini explains reasons for changes in shareholdings in CureVac due to legal restructuring and obligations under a share program

Retrieved on: 
Monday, October 18, 2021 - 7:01am

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Due to these changes and reduction in the beneficial ownership, the amendment was required by law without undue delay.
  • The amendment does not reflect any intent of dievini to exit its investment in CureVac nor does it change dievini's confidence in and commitment to CureVac.
  • dievini Hopp BioTech holding GmbH & Co. KG is a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies.

Novaliq Receives EU Quality Management Certificate According To New Medical Device Regulation (MDR)

Retrieved on: 
Tuesday, October 12, 2021 - 8:00am

On 26 May, 2021, the Medical Device Directive (MDD) has been replaced by the new Medical Device Regulation (MDR).

Key Points: 
  • On 26 May, 2021, the Medical Device Directive (MDD) has been replaced by the new Medical Device Regulation (MDR).
  • Manufacturers can place a CE (Conformit Europenne) mark on a medical device once it has passed a conformity assessment.
  • Some of these processes include device classification, technical file documentation, new responsibilities for the European Medicines Agency (EMA) and post-market activities.
  • An audit by mdc medical device certification GmbH has proven that Novaliq's quality management system fullfils the respective requirements and a conformity certificate has been issued in September 2021.

Novaliq Receives EU Quality Management Certificate According To New Medical Device Regulation (MDR)

Retrieved on: 
Tuesday, October 12, 2021 - 8:00am

On 26 May, 2021, the Medical Device Directive (MDD) has been replaced by the new Medical Device Regulation (MDR).

Key Points: 
  • On 26 May, 2021, the Medical Device Directive (MDD) has been replaced by the new Medical Device Regulation (MDR).
  • Manufacturers can place a CE (Conformit Europenne) mark on a medical device once it has passed a conformity assessment.
  • Some of these processes include device classification, technical file documentation, new responsibilities for the European Medicines Agency (EMA) and post-market activities.
  • An audit by mdc medical device certification GmbH has proven that Novaliq's quality management system fullfils the respective requirements and a conformity certificate has been issued in September 2021.

DGAP-News: trans-o-flex plans Initial Public Offering in Q4 2021

Retrieved on: 
Friday, September 17, 2021 - 8:01am

- In H1 2021, trans-o-flex generated 264 million in revenues and an adjusted EBITDA of 31 million showing robust growth despite COVID-19 impacts.

Key Points: 
  • - In H1 2021, trans-o-flex generated 264 million in revenues and an adjusted EBITDA of 31 million showing robust growth despite COVID-19 impacts.
  • - The Company intends to raise gross proceeds of at least 130 million from the sale of new shares.
  • The Company plans to complete the offering in the fourth quarter of 2021, subject to market conditions.
  • The Offering consists of an initial public offering in Germany and private placements in certain jurisdictions outside Germany.

DGAP-News: CompuGroup Medical SE: Annual General Meeting approves change of legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) and dividend at previous year's level

Retrieved on: 
Wednesday, May 13, 2020 - 5:05pm

CompuGroup Medical SE: Annual General Meeting approves change of legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) and dividend at previous year's level

Key Points: 
  • CompuGroup Medical SE: Annual General Meeting approves change of legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) and dividend at previous year's level
    The issuer is solely responsible for the content of this announcement.
  • CompuGroup Medical SE, one of the leading eHealth companies worldwide, held its Annual General Meeting, virtually, today for the first time.
  • With a majority of 75.67 %, the shareholders of the MDAX company decided to change its legal form into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA).
  • They will hold the same number of shares in KGaA as they hold in CompuGroup Medical SE prior to the change of legal form.